P/E at 36.02 vs Industry's 34.66: What the Data Shows for Sun Pharmaceutical Industries Ltd

Valuation Picture: Premium Amidst Sector Norms

The stock’s P/E ratio of 36.02 represents a modest premium of approximately 3.9% over the industry average of 34.66. This premium suggests that the market is pricing in a degree of growth or stability above the sector norm. However, the differential is not excessively stretched, indicating that valuation remains within a reasonable range relative to peers. The sector’s average P/E reflects a broad spectrum of companies, with some trading at significant discounts or premiums, so what is the current rating? for a stock with this valuation profile?

Performance Across Timeframes: Consistent Outperformance

Examining returns across multiple periods reveals that Sun Pharmaceutical Industries Ltd has consistently outperformed the Sensex. Over one year, the stock gained 12.21%, while the Sensex declined by 6.51%. Year-to-date, the stock is up 8.84% compared to the Sensex’s 9.22% loss. Even over three months, the stock’s 4.28% gain surpasses the Sensex’s 2.78% rise. This steady outperformance extends to longer horizons as well, with three-year returns at 88.71% versus the Sensex’s 22.84%, and five-year returns at 178.44% compared to 46.18% for the benchmark.

Short-term fluctuations are relatively muted, with the stock down 0.16% on the latest trading day, slightly underperforming the Sensex’s 0.49% gain. Over the past week, however, the stock has rebounded with a 2.62% rise, marginally ahead of the Sensex’s flat performance. This suggests a recent positive momentum shift — is this a genuine recovery or a relief rally that will fade at the 50 DMA? — which technical indicators can help clarify.

Moving Average Configuration: Bullish Across All Key Levels

The technical picture for Sun Pharmaceutical Industries Ltd is notably robust. The stock is trading above all major moving averages — the 5-day, 20-day, 50-day, 100-day, and 200-day averages. This alignment indicates a strong upward trend across both short and long-term horizons, a configuration often interpreted as bullish. The stock’s proximity to its 52-week high, just 2.16% away, further underscores this strength.

Such a comprehensive moving average breakout is relatively rare and suggests sustained buying interest. The stock has also recorded a seven-day consecutive gain, accumulating a 4.22% return in that period. This momentum contrasts with the broader sector, where out of 35 stocks reporting results, 19 have posted positive outcomes, 9 flat, and 7 negative, indicating a generally favourable environment but with pockets of caution.

Sector Context: Pharmaceuticals & Biotechnology Performance Snapshot

The Pharmaceuticals & Biotechnology sector has seen mixed results in recent reporting cycles. Of 35 stocks that declared results, 19 posted positive outcomes, 9 remained flat, and 7 reported negative results. This distribution suggests a cautiously optimistic sector environment, with a majority of companies showing resilience or growth. How does Sun Pharmaceutical Industries Ltd’s performance compare within this sector landscape? Its consistent outperformance and strong technicals position it favourably among peers.

Rating Context: Previously Rated Hold, Now Reassessed

According to MarketsMOJO, Sun Pharmaceutical Industries Ltd was previously rated Hold before the rating was updated on 08 Jun 2026. The reassessment reflects the evolving fundamentals and technical signals, including the valuation premium and sustained outperformance. The stock’s Mojo Score stands at 74.0, indicative of a strong overall profile. Should investors in Sun Pharmaceutical Industries Ltd hold, buy more, or reconsider?

Conclusion: A Balanced Data-Driven View

The data for Sun Pharmaceutical Industries Ltd paints a picture of a large-cap stock trading at a modest premium to its sector, supported by consistent outperformance across multiple timeframes. Its technical strength is evident in the stock’s position above all major moving averages and proximity to its 52-week high. The sector’s mixed but generally positive results provide a supportive backdrop.

While the stock’s valuation premium is not extreme, it does imply expectations of sustained performance. The recent rating reassessment from Hold reflects these evolving dynamics. Investors may find value in analysing the interplay of valuation, momentum, and sector context — what does the current rating suggest for portfolio strategy?

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →